Secondary Prevention of Small Subcortical Strokes (SPS3) Trial
Source: View publication →
The SPS3 trial investigated antiplatelet therapy and blood pressure management in patients with recent lacunar stroke, finding that dual antiplatelet therapy (aspirin plus clopidogrel) increased bleeding risks without reducing stroke recurrence compared to aspirin alone, while intensive blood pressure control (<130 mmHg) showed a trend toward benefit in reducing stroke risk.
Key Findings
Study Design
Study Limitations
Clinical Significance
The findings discourage the routine use of dual antiplatelet therapy (aspirin plus clopidogrel) for the secondary prevention of lacunar stroke, as the bleeding risk outweighs any potential benefit. The study supports a systolic blood pressure target of <130 mmHg as a safe and likely beneficial strategy for reducing stroke recurrence in patients with small vessel disease.
Historical Context
Prior to SPS3, the optimal secondary prevention strategies for lacunar stroke were unclear, and clinical practice varied. SPS3 was designed to address this knowledge gap by testing two therapeutic interventions in a large, systematic 2x2 factorial trial, setting a benchmark for evidence-based management of lacunar disease.
Guided Discussion
High-yield insights from every perspective
What are the primary pathophysiological differences between the 'small subcortical' (lacunar) strokes studied in SPS3 and large-vessel atherosclerotic strokes, and how does this explain the differing responses to dual antiplatelet therapy?
Key Response
Lacunar strokes are primarily caused by small-vessel lipohyalinosis or microatheromas in the penetrating arteries, rather than the large-vessel plaque rupture and high-burden thrombus formation seen in carotid or middle cerebral artery disease. Because the underlying mechanism in small-vessel disease is often more related to chronic hypertensive damage than to acute arterial-arterial embolism, the added antithrombotic benefit of dual antiplatelet therapy (DAPT) is lower, while the bleeding risk—particularly into damaged microvessels—is significantly higher.
Given the results of the SPS3 trial, how should you tailor the secondary prevention strategy for a patient who presents with a pure motor stroke and a corresponding 10mm infarct in the internal capsule, specifically regarding the choice of antiplatelet and blood pressure target?
Key Response
SPS3 demonstrated that for lacunar strokes, aspirin monotherapy is safer and just as effective as the combination of aspirin and clopidogrel, which was associated with increased mortality and bleeding. Regarding blood pressure, the trial suggests targeting a systolic BP of <130 mmHg. While the primary endpoint for stroke reduction in the BP arm was not statistically significant (p=0.08), there was a significant 63% reduction in the risk of intracranial hemorrhage, justifying more intensive control than the standard <140 mmHg.
SPS3 results for intensive blood pressure control (target <130 mmHg) showed a non-significant reduction in all strokes but a significant reduction in intracranial hemorrhage. How should this be integrated with the results of the later SPRINT trial when managing patients with cerebral small vessel disease (CSVD) and multiple lacunar infarcts?
Key Response
Fellows must synthesize evidence across trials. While SPS3 trended toward benefit, SPRINT later confirmed that intensive BP control (<120 mmHg) reduced cardiovascular events and mortality in high-risk patients. In the context of CSVD, the reduction in ICH found in SPS3 is a critical safety signal. This suggests that for patients with lacunar strokes, an intensive BP target is likely beneficial not just for primary prevention of future ischemic events, but specifically for mitigating the high hemorrhagic risk associated with fragile, small-vessel arteriopathy.
In the era of the POINT and CHANCE trials, which advocate for short-term DAPT in minor stroke, how do you differentiate 'minor stroke' from 'lacunar stroke' in the acute setting to ensure you are not inadvertently applying SPS3-ineligible management to your patients?
Key Response
This is a critical teaching point. POINT and CHANCE focused on high-risk TIA or minor ischemic strokes (NIHSS ≤3) mostly of large-vessel or embolic origin, where short-term (21-90 days) DAPT is beneficial. SPS3 showed that long-term DAPT is harmful in lacunar strokes. In practice, unless the stroke is clearly lacunar on urgent MRI (small, deep lesion) and lacks large-vessel stenosis, clinicians often start short-term DAPT for 'minor strokes' as per POINT; however, if the mechanism is confirmed as purely small-vessel disease, SPS3 guides us to transition back to monotherapy to avoid long-term harm.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
SPS3 utilized a 2x2 factorial design. What are the statistical and power implications of using this design when one intervention (DAPT) is terminated early for harm, and how might the presence or absence of an 'interaction effect' between blood pressure and antiplatelet intensity complicate the interpretation of the blood pressure arm?
Key Response
Factorial designs assume no interaction between treatments. If DAPT increased bleeding (which it did), and lower BP targets reduce bleeding (which they did), the two interventions could have a sub-additive or masking effect on the primary endpoint of total stroke. The early termination of the antiplatelet arm reduces the total person-years of follow-up for the BP arm within a factorial framework, potentially contributing to the 'near-significant' p-value (0.08) by reducing the power to detect the intended effect size.
As a reviewer, what concerns would you raise regarding the 'open-label' nature of the blood pressure intervention in SPS3 compared to the double-blind antiplatelet arm, and how does the achieve-target vs. intention-to-treat analysis impact the study's validity?
Key Response
Reviewers would flag potential performance bias; clinicians knew which patients were in the 'intensive' group and may have provided better overall care (the 'Hawthorne effect'). Furthermore, achieving a target of <130 mmHg is difficult; if a significant portion of the 'standard' group also achieved low BP, the contrast between groups narrows, leading to a type II error. Editors look for whether the trialists accounted for these cross-overs and if the monitoring was rigorous enough to ensure the BP separation was maintained throughout the study.
The 2021 AHA/ASA secondary stroke prevention guidelines recommend a BP target of <130/80 mmHg (Class I, LOE B-R). Given that the SPS3 primary endpoint for BP was not statistically significant, what specific secondary outcomes or meta-analyses including SPS3 justify this high level of recommendation?
Key Response
Guideline committees look beyond the primary p-value. The 'Class I' recommendation is justified by the significant reduction in intracranial hemorrhage (a devastating subtype of stroke) seen in SPS3, combined with evidence from SPRINT and meta-analyses showing a linear relationship between lower BP and reduced stroke risk. Despite the 0.08 p-value for 'all stroke,' the totality of the evidence—specifically the ICH prevention in a population prone to microhemorrhages—is viewed as practice-defining.
Clinical Landscape
Noteworthy Related Trials
PROGRESS Trial
Tested
Perindopril-based blood pressure lowering
Population
Patients with a history of stroke or TIA
Comparator
Placebo
Endpoint
Total stroke
SPS3 Antiplatelet Arm
Tested
Dual antiplatelet therapy (Clopidogrel + Aspirin)
Population
Patients with recent symptomatic lacunar stroke
Comparator
Aspirin alone
Endpoint
Recurrent stroke
SPS3 Trial
Tested
Intensive blood pressure control (<130 mm Hg)
Population
Patients with recent lacunar stroke
Comparator
Standard blood pressure control (130-149 mm Hg)
Endpoint
Recurrent stroke (ischemic or hemorrhagic)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis